ATE552344T1 - Viren mit erhöhter lytischer kraft - Google Patents

Viren mit erhöhter lytischer kraft

Info

Publication number
ATE552344T1
ATE552344T1 AT03729255T AT03729255T ATE552344T1 AT E552344 T1 ATE552344 T1 AT E552344T1 AT 03729255 T AT03729255 T AT 03729255T AT 03729255 T AT03729255 T AT 03729255T AT E552344 T1 ATE552344 T1 AT E552344T1
Authority
AT
Austria
Prior art keywords
viruses
target cells
increased lytic
functional
cells
Prior art date
Application number
AT03729255T
Other languages
English (en)
Inventor
Beusechem Victor Van
Willem-Ronald Gerritsen
Original Assignee
Vereniging Voor Christelijk Hoger Onderwijs Wetenschappelijk Onderzoek En Patientenzorg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vereniging Voor Christelijk Hoger Onderwijs Wetenschappelijk Onderzoek En Patientenzorg filed Critical Vereniging Voor Christelijk Hoger Onderwijs Wetenschappelijk Onderzoek En Patientenzorg
Application granted granted Critical
Publication of ATE552344T1 publication Critical patent/ATE552344T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03729255T 2002-01-14 2003-01-14 Viren mit erhöhter lytischer kraft ATE552344T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02075108A EP1327688A1 (de) 2002-01-14 2002-01-14 Adenoviren mit erhöhter Lysisfähigkeit
PCT/EP2003/000340 WO2003057892A2 (en) 2002-01-14 2003-01-14 Viruses with enhanced lytic potency

Publications (1)

Publication Number Publication Date
ATE552344T1 true ATE552344T1 (de) 2012-04-15

Family

ID=8185521

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03729255T ATE552344T1 (de) 2002-01-14 2003-01-14 Viren mit erhöhter lytischer kraft

Country Status (6)

Country Link
US (1) US8052965B2 (de)
EP (2) EP1327688A1 (de)
AT (1) ATE552344T1 (de)
AU (1) AU2003235764A1 (de)
ES (1) ES2385347T3 (de)
WO (1) WO2003057892A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005521398A (ja) * 2002-03-27 2005-07-21 ベイラー　カレッジ　オブ　メディスン 癌治療用の強力な腫瘍溶解性単純ヘルペスウイルス
US20110206639A1 (en) * 2004-04-15 2011-08-25 Christie Vermeulen Replication competent viruses capable of silencing virus inhibitory factor expression
EP1586654A1 (de) * 2004-04-15 2005-10-19 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Replikationskompetente Viren für Genabschaltung von Virusinaktivierungsfaktor
JP5284780B2 (ja) 2005-06-23 2013-09-11 ザ ユニバーシティ オブ ヒューストン 癌の治療のための単純ヘルペスウイルス２型変異体の使用
WO2007094653A1 (en) * 2006-02-13 2007-08-23 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Adenovirus particles having a chimeric adenovirus spike protein, use thereof and methods for producing such particles.
CN103122360A (zh) * 2006-02-28 2013-05-29 瓦克萨特公司 嵌合腺病毒载体
PT2043662E (pt) * 2006-07-26 2015-11-25 Intrexon Corp Métodos e composições para tratamento de doença
WO2011133040A2 (en) 2010-04-23 2011-10-27 Orca Therapeutics B.V. Replication-competent adenoviruses
WO2012047109A2 (en) 2010-10-08 2012-04-12 Orca Therapeutics B.V. Mirna and mirna inhibitors that modulate adenovirus replication and/or adenovirus induced cell death
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
CN112516179A (zh) 2013-06-14 2021-03-19 普赛奥克苏斯治疗公司 用于b型腺病毒的给药方案及制剂
GB201322851D0 (en) 2013-12-23 2014-02-12 Psioxus Therapeutics Ltd Method
SG11201602887QA (en) 2013-10-25 2016-05-30 Psioxus Therapeutics Ltd Oncolytic adenoviruses armed with heterologous genes
PL3198009T3 (pl) 2014-09-24 2022-01-24 Salk Institute For Biological Studies Onkolityczne wirusy nowotworowe i sposoby zastosowania
SG11201708604TA (en) 2015-04-30 2017-11-29 Psioxus Therapeutics Ltd Oncolytic adenovirus encoding a b7 protein
EA201891022A1 (ru) 2015-12-17 2019-01-31 Псайоксус Терапьютикс Лимитед Вирус, кодирующий антитело к комплексу tcr или фрагмент указанного антитела
CN105524161A (zh) * 2016-02-05 2016-04-27 南通大学 抗肿瘤小分子多肽piddδ及其载体和应用
JP7015551B2 (ja) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
JP7054527B2 (ja) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスの複製動態を測定するための高スループットアッセイ
MY197324A (en) 2016-08-29 2023-06-13 Akamis Bio Ltd Adenovirus armed with bispecific t cell activator
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
WO2018111767A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
JP7430395B2 (ja) 2018-04-09 2024-02-13 ソーク インスティテュート フォー バイオロジカル スタディーズ 複製特質が増強された腫瘍溶解性アデノウイルス組成物
US12233096B2 (en) 2018-08-31 2025-02-25 Orca Therapeutics B.V. Recombinant replication competent viruses comprising a coding region for glycogen synthase kinase-3 (GSK3) and methods of killing aberrant cells

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410010B1 (en) * 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
TW442569B (en) * 1993-10-25 2001-06-23 Canji Inc Recombinant adenoviral vector
US6638762B1 (en) * 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
US6133243A (en) * 1996-02-22 2000-10-17 Onyx Pharmaceuticals, Inc. Liposomal-viral DNA complexes for treating disease
ES2208942T3 (es) * 1996-07-05 2004-06-16 Philip E. Branton Proteinas e4 de adenovirus para inducir la muerte celular.
US5981275A (en) * 1997-04-14 1999-11-09 Genzyme Corporation Transgene expression system for increased persistence
US6100086A (en) * 1997-04-14 2000-08-08 Genzyme Corporation Transgene expression systems
AU2145300A (en) * 1998-11-18 2000-06-05 Canji, Inc. Adenoviral vectors
US6824771B1 (en) * 1999-05-12 2004-11-30 The Uab Research Foundation Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
FR2794025A1 (fr) * 1999-05-25 2000-12-01 Transgene Sa Composition destinee a la mise en oeuvre d'un traitement antitumoral ou antiviral chez un mammifere
DE60038508T2 (de) * 1999-07-15 2009-04-30 Introgen Therapeutics Inc., Austin Methoden zur behandlung von hyperproliferativen krankheiten mit menschlichem mda-7
CA2393844A1 (en) * 1999-12-14 2001-06-21 Genovo, Inc. Methods and compositions for the manufacture of replication incompetent adenovirus
AU3976900A (en) * 2000-04-04 2001-10-15 Christopher Barry Wood Combination of p53 gene and e1b-deleted p53 gene
WO2002088327A1 (en) * 2001-04-06 2002-11-07 Mount Sinai School Of Medicine Of New York University Methods for viral oncoapoptosis in cancer therapy

Also Published As

Publication number Publication date
EP1327688A1 (de) 2003-07-16
WO2003057892B1 (en) 2004-05-13
EP1466001B8 (de) 2012-11-21
WO2003057892A2 (en) 2003-07-17
US20050220765A1 (en) 2005-10-06
EP1466001A2 (de) 2004-10-13
AU2003235764A1 (en) 2003-07-24
WO2003057892A3 (en) 2004-02-26
US8052965B2 (en) 2011-11-08
ES2385347T3 (es) 2012-07-23
EP1466001B1 (de) 2012-04-04
AU2003235764A8 (en) 2003-07-24

Similar Documents

Publication Publication Date Title
EP1466001B8 (de) Viren mit erhöhter lytischer kraft
ES2134346T3 (es) Virus citopatico para el tratamiento y la profilaxis de la neoplasia.
DK1252323T3 (da) Virus-stammer til den onkolytiske behandling af cancer
KR20030025907A (ko) 카세인 유도 펩타이드 및 이들의 치료 용도
ATE277947T1 (de) Antitumorale zusammenstellung von immunogene polypetiden mit veränderter zellokalisierung
CY1106883T1 (el) Ανασυνδυασμενος ιος ευλογιας που περιεχει τουλαχιστον δυο υποκινητες ατι ιου ευλογιας αγελαδας.
BR0214650A (pt) Imunocitoquinas com seletividade modulada
FR2704234B1 (fr) Virus recombinants, preparation et utilisation en therapie genique.
HUE037330T2 (hu) rDEN3/4delta30(ME), rDEN2/4delta30(ME) vagy rDEN1/4delta30(ME) rekombináns kiméra dengue virus, amely 30 nukleotidos deléciót tartalmaz (delta 30) a 4-es típusú dengue genom 3' nem-transzlálódó régiójában, ahol a szóban forgó 30 nukleotidos deléció megfelel a TL2 nyél-hurok szerkezetnek
WO2002086100A3 (en) Expression of core-glycosylated hcv envelope proteins in yeast
BR0110573A (pt) Composto, composição farmacêutica que compreende esse composto, processo para a preparação de uma composição farmacêutica, utilização do composto e processo para o tratamento profilático ou terapêutico e para a preparação do composto
MXPA05005202A (es) Vacuna.
AR054599A1 (es) Proteccion de la proteina krp mutante negativa dominante contra una inhibicion activa del complejo cdk -ciclina por la krp de tipo salvaje
DE50208824D1 (de) Zusammensetzung zum zellspezifischen Transfer von Wirkstoffen
ES2185417T3 (es) Excipientes para usar en formulaciones farmaceuticas de virus adeno-asociados, y formulaciones farmaceuticas producidas con ellos.
ATE527356T1 (de) Replikationskompetente viren für genabschaltung von virusinaktivierung faktor
NO974179D0 (no) Rekombinante viruser som uttrykker lecitin-kolesterol-acyltransferase, og anvendelse derav i genterapi
WO2004035616A3 (de) Adenovirus mit umgekehrter reihenfolge der expression von genen und verwendung davon
IL75553A0 (en) Ache like peptide
WO2000066743A3 (en) Viral expression vectors
ATE531730T1 (de) Immunogene hybridpolypeptide mit wirkung gegen obesitas und diese enthaltende impstoffzusammensetzung mit wirkung gegen obesitas
ES2169040T3 (es) Planta resistente a dos o mas virus y preparacion de la misma.
AR033582A1 (es) Sistema de muerte celular en plantas
WO2003016474A3 (en) Methods and compositions for use in selectively producing a protein in telomerase expressing cells
DE60036929D1 (de) Gentherapeutika